drugset / Trial / NCT00094549

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

NCT00094549

Phase 4 Completed 500 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The goals of this study are: A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania. B. To assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients treated with olanzapine. C. To assess how olanzapine compares to divalproex.

Timeline

Start
2004-10
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Divalproex Sodium Small molecule 500 mg
Subject Divalproex Sodium Small molecule 2500 mg
Subject Olanzapine Small molecule 5 mg
Subject Olanzapine Small molecule 20 mg

Indications